Windy with rain and snow showers this evening transitioning to snow showers overnight. Low 32F. Winds WSW at 20 to 30 mph. Chance of precip 50%. Winds could occasionally gust over 40 mph..
Windy with rain and snow showers this evening transitioning to snow showers overnight. Low 32F. Winds WSW at 20 to 30 mph. Chance of precip 50%. Winds could occasionally gust over 40 mph.
Updated: January 19, 2023 @ 6:10 pm
Aligos Therapeutics Inc (NQ: ALGS )
1.190 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Headline News about Aligos Therapeutics Inc
LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million, including $55 million upfront plus royalties on sales. Meanwhile, Amoytop...
Via Talk Markets
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 15, 2023
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.
Recap: Aligos Therapeutics Q1 Earnings
May 04, 2023
Aligos Therapeutics Earnings Preview
May 03, 2023
A Preview Of Aligos Therapeutics's Earnings
March 08, 2023
Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud
September 29, 2022
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 17, 2023
Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program...
12 Health Care Stocks Moving In Monday's After-Market Session
January 16, 2023
12 Health Care Stocks Moving In Friday's Intraday Session
January 06, 2023
SVB Leerink Maintains Market Perform Rating for Aligos Therapeutics: Here's What You Need To Know
November 03, 2022
SVB Leerink has decided to maintain its Market Perform rating of Aligos Therapeutics (NASDAQ:ALGS) and lower its price target from $3.00 to $2.00. Shares of Aligos Therapeutics are trading up 0.0% over...
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
January 06, 2023
Aligos Therapeutics, Inc. (NASDAQ: ALGS) has initiated enrollment in a 12-week dosing cohort of HBeAg-positive chronic hepatitis B (CHB) subjects in the ongoing Phase 1b study ALG-000184-201.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following